long intergenic non-protein coding RNA 2463Genealiases: []
Q-omics provides the consensus-scored LINC02463 profile across patient tissues and cancer cell-line models. LINC02463 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC02463 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, LINC02463 RNA expression shows 6,893 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, BRCA, and STAD as cancer lineages where LINC02463 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02463 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02463 survival associations across molecular data types. LINC02463 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02463 RNA expression–survival associations across cancer types. High LINC02463 expression shows unfavorable associations in LIHC, OV, THCA, THYM and LGG, but favorable associations in HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC02463 RNA expression.
This table summarizes LINC02463 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02463. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02463 shows lower tumor expression in HNSC and higher tumor expression in BRCA, LUAD, PRAD, COAD and LUSC. The BRCA box plot shows higher LINC02463 RNA expression in tumor versus normal tissue (log2 FC = +0.270, t-test p < 0.001).
This table shows molecular features associated with LINC02463 in patient tissues and cancer cell lines. In patient samples, LINC02463 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
